Last updated: May 29, 2026
Trokendi XR suppliers: Which companies manufacture, supply, and contract for extended-release topiramate
Trokendi XR (topiramate extended-release) is supplied in the US by the marketed-product holder Amneal Pharmaceuticals (via affiliates/contract manufacturing arrangements historically used by branded generics and legacy topiramate XR supply chains). Production of oral solid extended-release products is typically split across (i) API/topiramate sourcing and (ii) finished-dose manufacturing and packaging.
Who are the Trokendi XR suppliers for the finished product and packaging?
Answer: Finished-dose supply for Trokendi XR is handled through contract manufacturing and packaging, with Amneal as the US marketer. The specific manufacturing site(s) and packaging line(s) are reflected in the FDA’s Drug Master File references and in cGMP facility listings tied to the approved NDA/ANDA manufacturing section, but a definitive “supplier list” requires tying the exact labeler/packager and manufacturing facility codes for the currently marketed package configuration.
What supplier categories support Trokendi XR?
- API supplier (topiramate)
- Topiramate is generally sourced from specialty chemical producers and then converted into extended-release dosage form by downstream finished-dose manufacturers.
- Finished-dose manufacturer
- Produces the extended-release matrix/tablet core, performs in-process controls, and completes tablet compression and XR-specific processes.
- Packager
- Handles bottle/blister packaging, carton packing, serialization (where applicable), and label application.
Where do you verify the actual manufacturing and packaging sites?
- FDA Orange Book NDA record (listed manufacturing/labeler references by application).
- FDA prescribing information “Manufactured for” / “Distributed by” statements (labeler and sponsor).
- FDA inspection/facility databases for the manufacturing site linked to the application.
- Drug listing data (NDC labeler) for package-level attribution to the marketing entity.
Which companies supply the topiramate API used to make Trokendi XR?
Answer: Topiramate API for US oral solid products is typically supplied by chemical manufacturers that produce pharmaceutical-grade topiramate and sell into multiple downstream dosage forms. For a branded XR product, the API vendor is often not named on the public label, so the practical supplier identification is done by:
- NDA manufacturing section site records,
- DMF holder links, and
- supplier disclosures in CMC sections (when public, usually through litigation exhibits or approvals history).
How to map API suppliers to Trokendi XR in practice
- Trace topiramate DMF references used by the NDA/ANDA manufacturing process.
- Cross-reference the API manufacturing facility names against publicly posted inspection records under the same legal manufacturer entity.
What Orange Book status does Trokendi XR have and how does that affect supplier consolidation?
Answer: Trokendi XR is an FDA-approved branded extended-release topiramate product. Orange Book listings typically show patents and (where applicable) exclusivities that influence whether supply chains stay consolidated under one marketer or fragment as generics enter.
Why Orange Book status matters for suppliers
- If multiple generics or authorized generics enter, contract manufacturing and packaging can shift across multiple dosage-form lines.
- If exclusivity is still active (including patent-protected method-of-use or formulation patents), the branded supplier chain tends to remain stable.
Which generic or authorized generic versions compete for the same supply slots?
Answer: Multiple topiramate extended-release generics compete in the US market under different NDAs/ANDAs, and that competition can drive:
- shared contract manufacturing capacity among dosage-form houses,
- reallocation of packaging lines,
- changes in NDC labelers and distribution partners.
How to identify shared supply
- Compare NDC labeler/manufacturer fields across competing XR products.
- Check whether the same finished-dose manufacturers appear across multiple products.
How do formulation and XR-specific manufacturing constraints limit supplier options?
Answer: Extended-release tablets require controlled-release technology that is sensitive to:
- polymer or matrix composition,
- drug particle characteristics,
- blending and granulation parameters,
- tablet compression and coating or matrix formation method,
- dissolution specifications by time-point.
Typical XR bottlenecks that constrain supplier pool
- Access to validated XR manufacturing platforms (equipment and process controls)
- Proven dissolution equivalence across strengths
- Stability and packaging compatibility
- Ability to support scale-up for multiple strengths without spec drift
What contract manufacturing and packaging model is used for Trokendi XR?
Answer: The standard model for branded oral solid drugs is:
- Amneal controls regulatory responsibility and market release,
- a contract manufacturer produces the dosage form under cGMP,
- a contract packager performs secondary packaging.
What to look for on the package label
- “Manufactured for” (drug product manufacturer)
- “Distributed by” (marketing authorization holder)
- NDC labeler codes that identify the entity responsible for listing and distribution
When do supplier and site changes typically occur for Trokendi XR?
Answer: Supplier changes tend to coincide with:
- NDA supplement approvals (manufacturing site changes),
- CMC updates (process validation refresh, equipment change),
- packaging format changes,
- post-approval manufacturing transfer during capacity rebalancing.
Timing signals
- FDA supplement approvals (site transfer, process change)
- Notice of changes in labeler/entity fields on NDC listings
- New packaging statements in prescriber information
Key Takeaways
- Trokendi XR supply is structured around FDA-authorized finished-dose manufacturing and packaging, with Amneal as the US marketer.
- Public labels usually do not name API vendors. Finished-dose and packaging entities are verified via NDA and NDC labeler/manufacturer fields and manufacturing-site records.
- XR-specific CMC constraints narrow supplier eligibility and tend to keep contract partners stable until CMC supplements or market-entry-driven capacity shifts occur.
- A complete supplier list for diligence and risk mapping requires tying the current product’s NDCs to their labeler and the linked manufacturing/packaging sites in FDA and NDC records.
FAQs
- How do I find the current NDC labeler for Trokendi XR and what does it indicate about suppliers?
- Which FDA records show the manufacturing and packaging facilities used for Trokendi XR?
- Do topiramate API suppliers change after Trokendi XR process or CMC supplements?
- What are the most common CMC reasons for switching contract manufacturers for extended-release tablets?
- How can I assess supplier risk (single-site dependence) for Trokendi XR using public regulatory data?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Trokendi XR entries). FDA.gov.
- FDA. Drugs@FDA. Trokendi XR NDA information and labeling. FDA.gov.
- FDA. National Drug Code (NDC) Directory. FDA.gov.
